scar reduction

Bonti Announces Results of Phase 2a Scar Reduction Clinical Study

EB-001A Clinical Trial Results

Bonti, a privately held, clinical-stage biotechnology company, announced topline results of its SHINE-1 (Scar Healing Improvement with Neurotoxin E) Phase 2a clinical trial, which evaluated the company’s EB-001A for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical profile, characterized by a faster onset of action (within 24 hours) and a shorter duration of activity (two to four weeks) compared to botulinum neurotoxin serotype A (BoNT/A) products.

Onion Extract May Reduce the Appearance of Scars

Once-daily application of a nonprescription onion extract gel (Mederma Advanced Scar Gel, Merz Pharmaceuticals, www.merz.com) softens and reduces the appearance of dermal scars, according to a study by Zoe Draelos, MD, et al, which appeared in the Journal of Clinical & Aesthetic Dermatology (June 2012). The randomized, controlled, single-blind study followed 44 adult subjects (male and female). Each of whom had two bilateral, 8mm seborrheic keratosis—one on the right and one on the left chest—surgically removed.